T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic

Written By Charlotte Kirby
Charlotte Kirby
Previous

ACF Investors: Why raising EIS limits is a budget imperative

Next

Paying it forward: The trailblazing Cambridge entrepreneurs engineering the next wave of global innovators